RxDoctor Payments Data

Kelley Hill, MD

Pulmonary Disease · Oxford, MSNPI 1063852473

Payments from drug & device makers

What this record shows

This record is dominated by education: $4,000 of the $6,102 with a category attached, or 65.6%. Intuitive Surgical accounts for 81.6% of it on its own, with 15 other manufacturers making up the rest. That places this record below the midpoint for pulmonary disease clinicians in MS, where the typical reported total is $4,861.

$6,102in general payments, 2019–2025

Across 52 payments — averaging $117.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Regeneron Healthcare Solutions, Inc.$148
  • GSK$147
  • Sanofi$140
  • Abiomed$118
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
  • plus $469 from 10 others

What the payments were for

  • Travel & lodging$80413%
  • Food & beverage$1,29821%
  • Education$4,00066%

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,102 in reported general payments places this provider in the 50th percentile of 101 pulmonary disease providers in Mississippi.

See all pulmonary disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$26,544
Medicare patients
102
Services billed
201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate13$170,811
Trelegy ElliptaFluticasone/Umeclidin/Vilanter129$104,080
Spiriva RespimatTiotropium Bromide32$22,580
Spiriva HandihalerTiotropium Bromide22$18,144
SymbicortBudesonide/Formoterol Fumarate33$11,597
Fluticasone-SalmeterolFluticasone Propion/Salmeterol46$7,171
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,563
Breo ElliptaFluticasone/Vilanterol14$5,433
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate24$5,220
Wixela InhubFluticasone Propion/Salmeterol43$5,117
Albuterol Sulfate HfaAlbuterol Sulfate142$4,519
BreynaBudesonide/Formoterol Fumarate11$3,487
Ventolin HfaAlbuterol Sulfate31$2,640
Montelukast Sodium71$667
Roflumilast14$605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$64$193,39145 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$147$115,075155 claims
AstraZenecaSymbicort$68$11,59733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 101 pulmonary disease providers in Mississippi.

Other pulmonary disease in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →